About
Lyotropic Delivery Systems (LDS) is a biotechnology company focusing on the development of drug delivery based on liquid nano-sized delivery systems. LDS's proprietary technology enables solubilizing large loads of poorly absorbed macromolecules, enhancing their transport across the gastrointestinal wall to the bloodstream without modifying the therapeutic compounds. This approach is based on the formation of modified soft and fluid gel mesophases with characteristics between a liquid and a crystal. The mesophases are composed of water nano-channels packed in unique symmetries, which are thermodynamically stable at various temperatures, resulting in long shelf life. LDS's portfolio comprises a range of projects including oral, ocular, and transdermal applications. The company's technology creates new uses for generic or innovative drugs, by using safe-to-use components, which are all categorized as generally recognized as safe and/or are listed within the FDA Inactive Ingredient Guide database.
Q&A
- What is LDS's primary focus?
- LDS is a biotechnology company that focuses on developing drug delivery systems based on liquid nano-sized delivery systems.
- What is the core technology behind LDS's drug delivery system?
- LDS's proprietary technology utilizes modified soft and fluid gel mesophases with characteristics between a liquid and a crystal. These mesophases contain water nano-channels packed in unique symmetries, which are thermodynamically stable and result in a long shelf life.
- What problems does LDS's technology aim to solve in drug delivery?
- LDS's technology enables the solubilization of large loads of poorly absorbed macromolecules, enhancing their transport across the gastrointestinal wall to the bloodstream without modifying the therapeutic compounds.
- What types of applications are included in LDS's project portfolio?
- LDS's portfolio comprises a range of projects including oral, ocular, and transdermal applications.
- What is the regulatory status of the components used in LDS's technology?
- The components used in LDS's technology are categorized as generally recognized as safe (GRAS) and/or are listed within the FDA Inactive Ingredient Guide database.
- When was LDS founded?
- LDS was founded in January 2012.
- Who are the founders of LDS?
- The founders of LDS are Nissim Garti, Prof., who serves as Founder & CEO, and Sharon Garti-Levi, PhD, who is the CTO & Co-founder.
- What is LDS's primary sector classification?
- LDS's primary sector is Health Tech & Life Sciences.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | lds-biotech.com |
|---|
Identifiers & details
| Founded | 2012-1 |
|---|---|
| Employees (exact) | 10 |
Radar intelligence
Patents
| EPO | 49 |
|---|
Publications (Crossref)
| Works | 10 |
|---|
Web history (Wayback)
| Domain | lds-biotech.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514708783 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2012-01-02 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 1 — annual_report (1) |
| Registered address | כפר הייטק 5 ירושלים |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-01 | דו~ח שנתי |